Director at Biocryst (NASDAQ: BCRX) sells 11,180 shares at $8.97

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC director Amy E. McKee sold 11,180 shares of common stock in an open-market transaction. The sale occurred at a weighted average price of $8.97 per share, with individual trade prices ranging from $8.96 to $8.985. Following the sale, she directly holds 31,252 shares of the company’s stock.

Insider Trade Summary

Net Seller: 11,180 shares ($100,285)

Net Sell 1 txn

Insider McKee Amy E

Role null

Sold 11,180 shs ($100K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,180	$8.97	$100K

Holdings After Transaction: Common Stock — 31,252 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 11,180 shares Weighted average sale price: $8.97 per share Post-transaction holdings: 31,252 shares +2 more

5 metrics

Shares sold 11,180 shares Open-market sale of common stock

Weighted average sale price $8.97 per share Price for 11,180 shares sold

Post-transaction holdings 31,252 shares Direct ownership after sale

Price range of trades $8.96–$8.985 Range for multiple sale transactions

Net shares sold 11,180 shares Net-sell direction in transaction summary

Key Terms

weighted average price, open-market sale, Form 4, transaction code "S"

4 terms

weighted average price financial

"The price in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code "S" regulatory

"transaction_code": "S","

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKee Amy E

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		S		11,180	D	$8.97(1)	31,252	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.96 to $8.985. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

	/s/ Alane P. Barnes, by power of attorney	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BIOCRYST PHARMACEUTICALS (BCRX) report for Amy E. McKee?

Amy E. McKee reported an open-market sale of BIOCRYST shares. She sold 11,180 shares of common stock in a single reported transaction, according to the Form 4 filing, reflecting a routine disposition rather than an acquisition of additional shares.

At what price did Amy E. McKee sell BIOCRYST (BCRX) shares in this Form 4?

The reported weighted average sale price was $8.97 per BIOCRYST share. The filing notes that individual trades occurred in multiple transactions within a price range from $8.96 to $8.985, resulting in the disclosed weighted average sale price.

How many BIOCRYST (BCRX) shares does Amy E. McKee hold after the reported sale?

After the transaction, Amy E. McKee directly holds 31,252 BIOCRYST shares. This post-transaction holding figure is disclosed in the Form 4 and shows her remaining direct ownership position following the 11,180-share open-market sale.

Was the BIOCRYST (BCRX) insider sale by Amy E. McKee an open-market transaction?

Yes, the Form 4 describes the transaction as an open-market sale. The filing uses transaction code “S” with the description “Sale in open market or private transaction,” and specifies a weighted average sale price with an accompanying price range disclosure.

Does the BIOCRYST (BCRX) Form 4 for Amy E. McKee include details on trade price ranges?

Yes, the Form 4 footnote provides the price range for the sale. It states that the 11,180 shares were sold in multiple transactions, with prices ranging from $8.96 to $8.985, and offers to provide full breakdowns upon request.